Targets

Targeting some of the world’s most common diseases

Many pharmaceutical companies have already attempted to find treatments for neurodegenerative diseases such as Parkinson’s and Alzheimer’s, generating drugs including Namenda, Reminyl, Exelon, and Aricept. However, at best these drugs have only modest benefits in treating the disease, and none of them are effective for more than a few months.

Unify has results which suggest that UP-1007 might be more successful. Unify is headquartered in Nashville, Tennessee, near the campus of internationally renowned Vanderbilt University.

PRIMARY INDICATIONS

PARKINSON’S DISEASE

The global market for treating Parkinson’s was worth $4 Billion USD in 2017 and is expected to rise to $8 Billion USD in 2026 at an annual growth rate of 8%.1

Over 10 million people worldwide have the disease, and by 2020 it is estimated that over 900,000 Americans will suffer from Parkinson’s.2

ALZHEIMER’S

The global market for treating Alzheimer’s was valued at $3 Billion USD in 2017 and is expected to rise to $6 Billion USD in 2024 at an annual growth rate of 8%.3

Over 30 million people around the world suffer from Alzheimer’s, and numbers have doubled every 20 years.4

MYOCARDIAL INFRACTION

The global market for cardiovascular devices treating heart attacks was $42 Billion USD in 2017 and will rise to $60 Billion USD in 2022 at an annual growth rate of 7%.5

The estimated annual incidence rate of heart attacks in the US is 720,000 new attacks and 335,000 recurrent attacks.6

STROKES

The global stroke management market was valued at $24.18 Billion USD in 2017 and is expected to rise to $35 Billion USD in 2023 at an annual growth rate of 7% by 2023.7

Strokes are one of the most widespread health problems in the world; approximately 1 in 6 people will suffer a stroke in their lifetimes.8

MACULAR DEGENERATION

Treatment for macular degeneration is worth $6 Billion in 2018 and will grow to $12 Billion USD in 2026.

Macular degeneration is the 3rd biggest cause of blindness in the world.14

Future market projections are based on the present standard of care, drugs available, and demographics. This does not account for the possible development of more effective drugs, which could drastically increase the market size.

SECONDARY INDICATIONS

BACK PAIN

The back-pain treatment market was worth $6 Billion USD in 2016 and will rise to nearly $10 Billion USD by 2025, at an annual growth rate of 5%.9

Back pain is one of the leading causes of disability in the world; over 540 million people suffer from it at any one time.10

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

The ALS treatment market is worth $250 Million USD in 2018 and is expected to rise to over $1 Billion USD by 2027, at an annual growth rate of 20%.12

ALS affects as many as 30,000 people in the US alone, and there are approximately 5,000 new cases each year.13